Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.

Article  PubMed  Google Scholar 

Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

Article  CAS  PubMed  Google Scholar 

Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.

Article  PubMed  Google Scholar 

Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4.

Article  PubMed  Google Scholar 

McGuire E. Bladder instability and stress incontinence. Neurourol Urodyn. 1988;7(6):563–7.

Article  Google Scholar 

Bates CP, Bradley WE, Glen ES, et al. Third Report on the Standardisation of Terminology of Lower Urinary Tract Function: procedures related to the evaluation of micturition: pressure-flow relationships. Residual urine. Br J Urol. 1980;52(5):348–50.

Article  Google Scholar 

Robinson D, Thiagamoorthy G, Cardozo L. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf. 2016;15(5):689–96.

Article  CAS  PubMed  Google Scholar 

Mirabegron. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed 2 September 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547887/

Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci. 2010;112(2):128–34.

Article  CAS  PubMed  Google Scholar 

Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39–45.

Article  CAS  PubMed  Google Scholar 

Ochodnicky P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol. 2012;9(11):628–37.

Article  CAS  PubMed  Google Scholar 

Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41.

Article  PubMed  Google Scholar 

Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005;174(2):604–7. https://doi.org/10.1097/01.ju.0000165461.38088.7b.

Article  PubMed  Google Scholar 

Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(Suppl 4):S7–18.

PubMed  PubMed Central  Google Scholar 

Coelho A, Oliveira R, Antunes-Lopes T, Duarte Cruz C. Partners in crime: NGF and BDNF in visceral dysfunction. Curr Neuropharmacol. 2019;17(11):1021–38. https://doi.org/10.2174/1570159X17666190617095844.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuk SM, Shin JH, Song KH, Na YG, Lim JS, Sul CK. Expression of brain derived-neurotrophic factor and granulocyte-colony stimulating factor in the urothelium: relation with voiding function. BMC Urol. 2015;15:37. https://doi.org/10.1186/s12894-015-0036-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng C, Li Q, Lin G, Opara EC, Zhang Y. Neurobiological insights into lower urinary tract dysfunction: evaluating the role of brain-derived neurotrophic factor. Am J Clin Exp Urol. 2023;11(6):559–77

PubMed  PubMed Central  Google Scholar 

Kashyap MP, Pore SK, de Groat WC, Chermansky CJ, Yoshimura N, Tyagi P. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Renal Physiol. 2018;315(1):F45–56.

Article  CAS  PubMed  Google Scholar 

Tsiapakidou S, Apostolidis A, Pantazis K, Grimbizis GF, Mikos T. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Int Urogynecol J. 2021;32(12):3143–55.

Article  PubMed  Google Scholar 

Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2011;107(5):799–803.

Article  CAS  PubMed  Google Scholar 

Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1)):359–65. https://doi.org/10.1016/j.juro.2012.08.187

Article  CAS  PubMed  Google Scholar 

Suh YS, Ko KJ, Kim TH, et al. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients. Int Neurourol J. 2017;21(4):270–81.

Article  PubMed  PubMed Central  Google Scholar 

Sağır S, Bayrak Ö, Şen H, Kul S, Erturhan S, Seçkiner İ. Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection. Turk J Urol. 2021;47(3):223–8.

Article  PubMed  Google Scholar 

Birder LA, Wolf-Johnston AS, Sun Y, Chai TC. Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf). 2013;207(1):123–9.

Article  CAS  PubMed  Google Scholar